Mario Masellis, MSc, MD, PhD, Cognitive and Movement Disorders Clinic, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, Tel: 416-480-6100 ext. 89351, Fax: 416-480-5354, Email:
J Prev Alzheimers Dis. 2024;11(4):975-982. doi: 10.14283/jpad.2024.85.
Alzheimer's disease is a neurodegenerative disorder marked by cognitive decline and brain pathology involving amyloid plaques and neurofibrillary tangles. Current drug development focuses on disease-modifying therapies, primarily antibodies targeting amyloid or tau. However, the blood-brain barrier (BBB) poses a challenge for drug delivery to the brain. Pre- and early clinical data suggests that Focused Ultrasound (FUS) technology safely enhances BBB permeability without damaging brain tissue, enabling drug delivery. This systematic review discusses the application of FUS to open the BBB for the treatment of Alzheimer's disease (AD). We review the safety, efficacy, and potential biological effects of FUS-mediated BBB opening in AD patients.
阿尔茨海默病是一种神经退行性疾病，其特征是认知能力下降和大脑病理学，涉及淀粉样斑块和神经原纤维缠结。目前的药物开发侧重于疾病修饰疗法，主要是针对淀粉样蛋白或 tau 的抗体。然而，血脑屏障（BBB）对药物向大脑的输送构成了挑战。临床前和早期临床数据表明，聚焦超声（FUS）技术可安全地增强 BBB 的通透性，而不会损害脑组织，从而实现药物输送。本系统评价讨论了 FUS 在治疗阿尔茨海默病（AD）中打开 BBB 的应用。我们回顾了 FUS 介导的 BBB 开放在 AD 患者中的安全性、疗效和潜在生物学效应。
Zotero 插件